{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:33:43Z","timestamp":1793453623044,"version":"4.5.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473067"],"award-info":[{"award-number":["82473067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82673750"],"award-info":[{"award-number":["82673750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mtbio.2026.103740","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:52:40Z","timestamp":1791503560000},"page":"103740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation"],"prefix":"10.1016","volume":"41","author":[{"given":"Haoyuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0414-6314","authenticated-orcid":false,"given":"Wanying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siru","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-4765","authenticated-orcid":false,"given":"Jianbin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2026.103740_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mtbio.2026.103740_bib2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mtbio.2026.103740_bib3","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mtbio.2026.103740_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mtbio.2026.103740_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mtbio.2026.103740_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.semcancer.2022.05.014","article-title":"Nanomedicine for urologic cancers: diagnosis and management","volume":"86","author":"Li","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.mtbio.2026.103740_bib13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.mtbio.2026.103740_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124623","article-title":"Prostate cancer chemotherapy by intratumoral administration of docetaxel-mesoporous silica nanomedicines","volume":"664","author":"Rivero-Buceta","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103740_bib16","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/ERC-12-0085","article-title":"The reactive stroma microenvironment and prostate cancer progression","volume":"19","author":"Barron","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mtbio.2026.103740_bib17","first-page":"1005","article-title":"Image-guided renal intervention","volume":"53","author":"Frey","year":"2015","journal-title":"Radiol. Clin."},{"key":"10.1016\/j.mtbio.2026.103740_bib18","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1038\/s41598-022-12334-x","article-title":"Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads","volume":"12","author":"Bi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103740_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103740_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mtbio.2026.103740_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib23","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"Kiess","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.mtbio.2026.103740_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061195","article-title":"CD44 in bladder cancer","volume":"16","author":"Duex","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mtbio.2026.103740_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197146","article-title":"Carbonic anhydrase IX in renal cell carcinoma, implications for disease management","volume":"21","author":"Courcier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122724","article-title":"Local drug delivery in bladder cancer: advances of Nano\/micro\/macro-scale drug delivery systems","volume":"15","author":"Marchenko","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/acsomega.8b02909","article-title":"PSMA-targeted mesoporous silica nanoparticles for selective intracellular delivery of docetaxel in prostate cancer cells","volume":"4","author":"Rivero-Buceta","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.mtbio.2026.103740_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121609","article-title":"Gemcitabine-loaded microbeads for transarterial chemoembolization of rabbit renal tumor monitored by (18)F-FDG positron emission Tomography\/X-Ray computed tomography imaging","volume":"16","author":"Zhang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib30","article-title":"A study on the effectiveness and safety of interventional embolization using drug-loaded microspheres in combination with sorafenib and envafolimab for intermediate and advanced renal cell carcinoma","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1600-0854.2003.00156.x","article-title":"The uroepithelium: not just a passive barrier","volume":"5","author":"Apodaca","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.mtbio.2026.103740_bib32","doi-asserted-by":"crossref","first-page":"F1477","DOI":"10.1152\/ajprenal.00327.2009","article-title":"Cell biology and physiology of the uroepithelium","volume":"297","author":"Khandelwal","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.mtbio.2026.103740_bib33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091415","article-title":"Cannabidiol effectively promoted cell death in bladder cancer and the improved intravesical adhesion drugs delivery strategy could be better used for treatment","volume":"13","author":"Chen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1208\/s12249-020-01752-7","article-title":"Catechol-functionalized alginate nanoparticles as mucoadhesive carriers for intravesical chemotherapy","volume":"21","author":"Sahatsapan","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.mtbio.2026.103740_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jconrel.2020.03.028","article-title":"Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer","volume":"324","author":"Xu","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s12951-025-03594-6","article-title":"Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes for enhancing the PDT of bladder cancer","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112696119","article-title":"Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer","volume":"119","author":"Kong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mtbio.2026.103740_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijpharm.2016.08.026","article-title":"Adhesion of thiolated silica nanoparticles to urinary bladder mucosa: effects of PEGylation, thiol content and particle size","volume":"512","author":"Mun","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103740_bib40","doi-asserted-by":"crossref","first-page":"52374","DOI":"10.1021\/acsami.1c14944","article-title":"Intravesical mucoadhesive hydrogel induces chemoresistant bladder cancer ferroptosis through delivering iron oxide nanoparticles in a three-tier strategy","volume":"13","author":"Qi","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103740_bib41","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of bacillus Calmette-Gu\u00e9rin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103740_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12951-024-02816-7","article-title":"A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery","volume":"22","author":"Zheng","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib43","doi-asserted-by":"crossref","first-page":"10273","DOI":"10.1039\/D4NR01128G","article-title":"NIR-II light powered hydrogel nanomotor for intravesical instillation with enhanced bladder cancer therapy","volume":"16","author":"Chen","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.mtbio.2026.103740_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2016.12.041","article-title":"Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma","volume":"259","author":"Guo","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.12.015","article-title":"Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors","volume":"371","author":"Bilensoy","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103740_bib46","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.18632\/oncotarget.13578","article-title":"Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mtbio.2026.103740_bib47","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1039\/c3tb21625j","article-title":"Bifunctional pH-sensitive Zn(ii)-curcumin nanoparticles\/siRNA effectively inhibit growth of human bladder cancer cells in vitro and in vivo","volume":"2","author":"Xing","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.mtbio.2026.103740_bib48","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.2147\/IJN.S140111","article-title":"Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation","volume":"12","author":"Qiu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2026.103740_bib49","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1021\/acsnano.9b09726","article-title":"Urease-powered polydopamine nanomotors for intravesical therapy of bladder diseases","volume":"14","author":"Choi","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121061","article-title":"Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models","volume":"277","author":"Tan","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103740_bib51","doi-asserted-by":"crossref","first-page":"46668","DOI":"10.1021\/acsami.3c09564","article-title":"Hyaluronic acid-conjugated fluorescent probe-shielded polydopamine nanomedicines for targeted imaging and chemotherapy of bladder cancer","volume":"15","author":"Qiu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103740_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114246","article-title":"Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy","volume":"387","author":"Miao","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib53","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","article-title":"Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","volume":"15","author":"Choi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103740_bib54","doi-asserted-by":"crossref","first-page":"735","DOI":"10.34133\/research.0735","article-title":"A multifunctional Fe-EGCG@RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy","volume":"8","author":"Zhang","year":"2025","journal-title":"Research"},{"key":"10.1016\/j.mtbio.2026.103740_bib55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12951-022-01575-7","article-title":"Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation","volume":"20","author":"Chin","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib57","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s13346-020-00868-4","article-title":"Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies","volume":"11","author":"Verco","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib58","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.2147\/IJN.S466396","article-title":"Synergistic potential of nanomedicine in prostate cancer immunotherapy: Breakthroughs and prospects","volume":"19","author":"Jiang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2026.103740_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2025.06.002","article-title":"Analysis of the current surgical anatomical knowledge of radical prostatectomy: an updated review","volume":"89","author":"Mandel","year":"2026","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122835","article-title":"Bioresorbable nonwoven patches as taxane delivery systems for prostate cancer treatment","volume":"14","author":"Jaworska","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mtbio.2026.103740_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173098","article-title":"Developmental therapeutics in metastatic prostate cancer: new targets and new strategies","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mtbio.2026.103740_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.757428","article-title":"Injectable hydrogel for synergetic low dose radiotherapy, chemodynamic therapy and photothermal therapy","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib66","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1021\/acs.nanolett.0c02487","article-title":"Targeted radiosensitizers for MR-Guided radiation therapy of prostate cancer","volume":"20","author":"Luo","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103740_bib67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.prp.2014.12.009","article-title":"The normal and pathologic renal medulla: a comprehensive overview","volume":"211","author":"L\u00f3pez","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.mtbio.2026.103740_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500657","article-title":"Nanomedical strategies for kidney disease: diagnostic innovations and therapeutic advancements","volume":"14","author":"Yao","year":"2025","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12951-022-01761-7","article-title":"Nanomedicine for renal cell carcinoma: imaging, treatment and beyond","volume":"21","author":"Wu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fradi.2025.1559411","article-title":"Adjunctive techniques for renal cell carcinoma ablation: an update","volume":"5","author":"Torres","year":"2025","journal-title":"Front Radiol."},{"key":"10.1016\/j.mtbio.2026.103740_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2016.07.041","article-title":"Local arterial wall drug delivery using balloon catheter system","volume":"238","author":"Tesfamariam","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2020.11.051","article-title":"Target delivery of drug carriers in mice kidney glomeruli via renal artery. Balance between efficiency and safety","volume":"329","author":"Prikhozhdenko","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1089\/end.2023.0705","article-title":"Local renal treatments for acute kidney injury: a review of current progress and future translational opportunities","volume":"38","author":"Chen","year":"2024","journal-title":"J. Endourol."},{"key":"10.1016\/j.mtbio.2026.103740_bib74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737140.2019.1571915","article-title":"Percutaneous renal mass biopsy: historical perspective, current status, and future considerations","volume":"19","author":"Cotta","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.mtbio.2026.103740_bib75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11547-014-0412-1","article-title":"Radiofrequency thermal ablation of renal tumors","volume":"119","author":"De Filippo","year":"2014","journal-title":"Radiol. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.diii.2016.12.002","article-title":"Microwave ablation of renal tumors: a narrative review of technical considerations and clinical results","volume":"98","author":"Cornelis","year":"2017","journal-title":"Diagn. Interventional Imaging"},{"key":"10.1016\/j.mtbio.2026.103740_bib77","article-title":"3D-CEUS tracking of injectable chemo-sonodynamic therapy-enabled mop-up of residual renal cell carcinoma after thermal ablation","volume":"18","author":"Li","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103740_bib78","article-title":"Biomimetic hydrogel-mediated mechano-immunometabolic therapy for inhibition of ccRCC recurrence after surgery","volume":"11","author":"Dong","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.mtbio.2026.103740_bib79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.actbio.2015.10.024","article-title":"Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-\u03b1 and sorafenib on renal cell carcinoma cells","volume":"29","author":"Ueda","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.mtbio.2026.103740_bib80","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-Human safety, imaging, and dosimetry of a carbonic anhydrase IX-Targeting peptide, [(68)Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib81","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.7150\/thno.96944","article-title":"Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Kleinendorst","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2026.103740_bib82","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s10637-020-00922-5","article-title":"Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and treg levels in peripheral blood","volume":"38","author":"Maulhardt","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.mtbio.2026.103740_bib83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/14728214.2015.1047761","article-title":"Emerging tyrosine kinase inhibitors for the treatment of renal cancer","volume":"20","author":"Iacovelli","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.mtbio.2026.103740_bib84","article-title":"Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer","volume":"12","author":"Zhao","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103740_bib85","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2174\/0113894501384020250804093144","article-title":"Development of novel intravesical formulation for bladder retention targeting bladder disorders","volume":"26","author":"Harle","year":"2025","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.mtbio.2026.103740_bib86","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-20-3095","article-title":"Androgen receptor regulates CD44 expression in bladder cancer","volume":"81","author":"Sottnik","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2016.02.040","article-title":"Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy","volume":"228","author":"Schaal","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020315","article-title":"PSMA-targeted nanotheranostics for imaging and radiotherapy of prostate cancer","volume":"16","author":"Meher","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mtbio.2026.103740_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123177","article-title":"Iodixanol as a new contrast agent for cyanoacrylate embolization: a preliminary in vivo swine study","volume":"11","author":"Guillen","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.mtbio.2026.103740_bib90","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2174\/1568026620666200825170030","article-title":"Multifunctional nanoparticles in precise cancer treatment: considerations in design and functionalization of nanocarriers","volume":"20","author":"Lu","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mtbio.2026.103740_bib91","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41586-020-2612-2","article-title":"Effects of extracellular matrix viscoelasticity on cellular behaviour","volume":"584","author":"Chaudhuri","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103740_bib92","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2020.09.059","article-title":"Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition","volume":"183","author":"Priem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103740_bib93","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-021-05580-0","article-title":"The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection","volume":"49","author":"Wit","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.mtbio.2026.103740_bib94","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1021\/acsnano.8b06610","article-title":"Targeting 3D bladder cancer spheroids with urease-powered nanomotors","volume":"13","author":"Hortel\u00e3o","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13046-024-03146-0","article-title":"Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy","volume":"43","author":"Liang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib96","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/acsabm.8b00524","article-title":"A specific drug delivery system for targeted accumulation and tissue penetration in prostate tumors based on microbially synthesized PHBHHx biopolyester and iRGD peptide fused PhaP","volume":"1","author":"Fan","year":"2018","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib97","article-title":"PSMA-targeted supramolecular nanoparticles prepared from Cucurbit[8]uril-Based ternary host-guest recognition for prostate cancer therapy","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.mtbio.2026.103740_bib98","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S596277","article-title":"CA9-Targeted liposomal delivery of siETS1 inhibits clear cell renal cell carcinoma progression by disrupting the ETS1\/MYC regulatory axis","volume":"21","author":"Ye","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2026.103740_bib99","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/17425247.2020.1810016","article-title":"Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer","volume":"17","author":"Yoon","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mtbio.2026.103740_bib100","article-title":"Nanoparticles as drug delivery systems in intravesical therapy for non-muscle invasive bladder cancer: a narrative review","volume":"17","author":"G\u00f3rski","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.mtbio.2026.103740_bib101","article-title":"Emerging technologies for local cancer treatment","volume":"3","author":"Chua","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.mtbio.2026.103740_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2018.04.034","article-title":"Bioadhesives for internal medical applications: a review","volume":"74","author":"Zhu","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.mtbio.2026.103740_bib103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0975-7406.76478","article-title":"Mucoadhesive drug delivery systems","volume":"3","author":"Shaikh","year":"2011","journal-title":"J. Pharm. BioAllied Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib104","first-page":"7499","volume":"vol 2229","author":"Tangri","year":"2011"},{"key":"10.1016\/j.mtbio.2026.103740_bib105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0378-5173(00)00396-3","article-title":"An atomic force microscopy investigation of bioadhesive polymer adsorption onto human buccal cells","volume":"200","author":"Patel","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103740_bib106","article-title":"Exploring bioadhesion: insight on innovative strategies to investigate bioadhesive scaffolds","volume":"10","author":"Pollini","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.mtbio.2026.103740_bib107","series-title":"Bioadhesive Drug Delivery","author":"Leung","year":"1990"},{"key":"10.1016\/j.mtbio.2026.103740_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202100231","article-title":"Rational engineering and applications of functional bioadhesives in biomedical engineering","volume":"16","author":"Park","year":"2021","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.mtbio.2026.103740_bib109","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1039\/C9CS00285E","article-title":"Catechol-functionalized hydrogels: biomimetic design, adhesion mechanism, and biomedical applications","volume":"49","author":"Zhang","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib110","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/jacs.6b13149","article-title":"Perspectives on mussel-inspired wet adhesion","volume":"139","author":"Ahn","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mtbio.2026.103740_bib111","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-026-03415-2","article-title":"Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives","volume":"43","author":"Khan","year":"2026","journal-title":"Med. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib112","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.11.031","article-title":"Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery","volume":"245","author":"GuhaSarkar","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib113","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients","volume":"10","author":"Berinstein","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.progpolymsci.2020.101243","article-title":"The swollen polymer network hypothesis: quantitative models of hydrogel swelling, stiffness, and solute transport","volume":"105","author":"Richbourg","year":"2020","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib115","doi-asserted-by":"crossref","first-page":"7953","DOI":"10.1021\/acsnano.2c12448","article-title":"Nanoarchitecture-integrated hydrogel systems toward therapeutic applications","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib116","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s10439-016-1583-9","article-title":"Nanoparticle-hydrogel: a hybrid biomaterial system for localized drug delivery","volume":"44","author":"Gao","year":"2016","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.103740_bib117","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1021\/acsnano.5b01433","article-title":"Nanocomposite hydrogels: 3D polymer-nanoparticle synergies for On-Demand drug delivery","volume":"9","author":"Merino","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115083","article-title":"Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer","volume":"202","author":"Mikhail","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib119","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0006-3495(96)79645-5","article-title":"Hindered diffusion in agarose gels: test of effective medium model","volume":"70","author":"Johnson","year":"1996","journal-title":"Biophys. J."},{"key":"10.1016\/j.mtbio.2026.103740_bib120","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1021\/acs.macromol.9b00753","article-title":"A multiscale model for solute diffusion in hydrogels","volume":"52","author":"Axpe","year":"2019","journal-title":"Macromolecules"},{"key":"10.1016\/j.mtbio.2026.103740_bib121","article-title":"In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy","volume":"14","author":"Li","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103740_bib122","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2019.12.024","article-title":"Charge-reversal nanocarriers: an emerging paradigm for smart cancer nanomedicine","volume":"319","author":"Zhang","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.12.002","article-title":"Unveiling cytokine charge disparity as a potential mechanism for immune regulation","volume":"77","author":"Messina","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib124","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1021\/nl101140t","article-title":"Effect of nanoparticle surface charge at the plasma membrane and beyond","volume":"10","author":"Arvizo","year":"2010","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103740_bib125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/17425241003603653","article-title":"Electrostatic surface modifications to improve gene delivery","volume":"7","author":"Shmueli","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mtbio.2026.103740_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12353","article-title":"Critical considerations in determining the surface charge of small extracellular vesicles","volume":"12","author":"Tamrin","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.mtbio.2026.103740_bib127","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9954443","article-title":"Toxicity of nanoparticles in biomedical application: Nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"10.1016\/j.mtbio.2026.103740_bib128","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1556-276X-6-480","article-title":"Cytotoxic effects and the mechanism of three types of magnetic nanoparticles on human hepatoma BEL-7402 cells","volume":"6","author":"Kai","year":"2011","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.mtbio.2026.103740_bib129","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acs.accounts.9b00103","article-title":"Nano-cell interactions of non-cationic bionanomaterials","volume":"52","author":"Ho","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/polym14132601","article-title":"Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect","volume":"14","author":"Ejigah","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.mtbio.2026.103740_bib131","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00294770","article-title":"Ultrastructural visualization of human bladder mucous","volume":"18","author":"Cornish","year":"1990","journal-title":"Urol. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib132","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1016\/j.apsb.2024.07.003","article-title":"Strategies for intravesical drug delivery: from bladder physiological barriers and potential transport mechanisms","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2026.103740_bib133","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184412","article-title":"Prostate cancer tumor stroma: responsibility in tumor biology, diagnosis and treatment","volume":"14","author":"Gonz\u00e1lez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mtbio.2026.103740_bib135","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.leu.2402179","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR\/ABL inhibition, cytotoxic drugs, and gamma-irradiation","volume":"15","author":"Damiano","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103740_bib136","doi-asserted-by":"crossref","first-page":"20825","DOI":"10.1021\/acsnano.3c05853","article-title":"Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib137","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1021\/nn3057005","article-title":"Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo","volume":"7","author":"Niikura","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103740_bib138","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/nl900031y","article-title":"Mediating tumor targeting efficiency of nanoparticles through design","volume":"9","author":"Perrault","year":"2009","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103740_bib139","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib140","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib141","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib142","volume":"14","author":"Munir","year":"2022","journal-title":"Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue, Cancers (Basel)"},{"key":"10.1016\/j.mtbio.2026.103740_bib143","article-title":"Nanoparticle accumulation and penetration in 3D tumor models: the effect of size, shape, and surface charge","volume":"12","author":"Cybulski","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mtbio.2026.103740_bib144","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1073\/pnas.1018382108","article-title":"Multistage nanoparticle delivery system for deep penetration into tumor tissue","volume":"108","author":"Wong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mtbio.2026.103740_bib145","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.apsb.2024.11.012","article-title":"Size-transformable nanotherapeutics for cancer therapy","volume":"15","author":"Ma","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2026.103740_bib146","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2026.103740_bib147","first-page":"1","article-title":"Prostate cancer stroma: an important factor in cancer growth and progression","volume":"15","author":"Kru\u0161lin","year":"2015","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib148","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrurol.2011.44","article-title":"Matrix metalloproteinases and their clinical relevance in urinary bladder cancer","volume":"8","author":"Szarvas","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.mtbio.2026.103740_bib150","article-title":"Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines","volume":"16","author":"Li","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103740_bib151","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2015.08.017","article-title":"Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors","volume":"219","author":"Miao","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib152","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib153","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrurol.2015.292","article-title":"The interplay of extracellular matrix and microbiome in urothelial bladder cancer","volume":"13","author":"Alfano","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib154","first-page":"11","article-title":"Harnessing extracellular matrix biology for tumor drug delivery","author":"Subrahmanyam","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13058-015-0609-9","article-title":"Targeting lysyl oxidase for molecular imaging in breast cancer","volume":"17","author":"Wuest","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib156","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib157","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/D0BM01755H","article-title":"Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics","volume":"9","author":"Desale","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib159","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2015.01.011","article-title":"Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation","volume":"201","author":"Kadonosono","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1535-7163.MCT-13-0502","article-title":"Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer","volume":"13","author":"Martin","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.mtbio.2026.103740_bib161","doi-asserted-by":"crossref","first-page":"37782","DOI":"10.18632\/oncotarget.5622","article-title":"Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.mtbio.2026.103740_bib162","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1166\/jbn.2018.2499","article-title":"Novel application of cell penetrating R11 peptide for diagnosis of bladder cancer","volume":"14","author":"Du","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib163","first-page":"416","article-title":"Tumor microenvironment responsive drug delivery systems","volume":"15","author":"He","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010146","article-title":"Matrix metalloproteinases shape the tumor microenvironment in cancer progression","volume":"23","author":"Niland","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2017.01.034","article-title":"Matrix-metalloproteinases as targets for controlled delivery in cancer: an analysis of upregulation and expression","volume":"259","author":"Isaacson","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512311","article-title":"The bladder tumor microenvironment components that modulate the tumor and impact therapy","volume":"24","author":"Patwardhan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103740_bib167","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/acs.accounts.0c00475","article-title":"Nano-immune-engineering approaches to advance cancer immunotherapy: lessons from ultra-ph-sensitive nanoparticles","volume":"53","author":"Li","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib168","first-page":"1194","article-title":"Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer","volume":"56","author":"Gerweck","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib169","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2007.12.017","article-title":"A review of stimuli-responsive nanocarriers for drug and gene delivery","volume":"126","author":"Ganta","year":"2008","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","article-title":"Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review","volume":"85","author":"Kanamala","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103740_bib171","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1039\/C7CS00663B","article-title":"Development of endogenous enzyme-responsive nanomaterials for theranostics","volume":"47","author":"Mu","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib172","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1038\/s41598-021-86888-7","article-title":"Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma","volume":"11","author":"Ahluwalia","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103740_bib173","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s13277-013-1395-6","article-title":"The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis","volume":"35","author":"Yan","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.mtbio.2026.103740_bib174","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12672-025-02552-w","article-title":"Cathepsin B in urological tumors: unraveling its role and therapeutic potential","volume":"16","author":"Yan","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib175","article-title":"Engineering exosome membrane disguised thermal responsive system for targeted drug delivery and controlled release across the blood-brain barrier","volume":"32","author":"Han","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103740_bib176","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1039\/D1SM00999K","article-title":"Photo-responsive polymeric nanocarriers for target-specific and controlled drug delivery","volume":"17","author":"Mart\u00edn Gim\u00e9nez","year":"2021","journal-title":"Soft Matter"},{"key":"10.1016\/j.mtbio.2026.103740_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121906","article-title":"Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy","volume":"291","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103740_bib178","article-title":"Hyaluronic acid-based hydrogel microspheres with multi-responsive properties for antibacterial therapy and bone regeneration in staphylococcus aureus-infected skull defects","volume":"32","author":"Lin","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2026.103740_bib179","doi-asserted-by":"crossref","first-page":"59682","DOI":"10.1021\/acsami.4c12603","article-title":"Emerging strategies for local delivery of immune checkpoint inhibitors to potentiate cancer immunotherapy: current status and future prospects","volume":"16","author":"Chen","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103740_bib180","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx097","article-title":"Local immunotherapy of cancer: innovative approaches to harnessing tumor-specific immune responses","volume":"109","author":"Murthy","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mtbio.2026.103740_bib181","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2016.11.014","article-title":"Tumor-targeted nanomedicines for cancer theranostics","volume":"115","author":"Arranja","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib182","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib183","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","article-title":"Intravesical treatments of bladder cancer: review","volume":"25","author":"Shen","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib184","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020166","article-title":"Strategies to get drugs across bladder penetrating barriers for improving bladder cancer therapy","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib185","doi-asserted-by":"crossref","first-page":"21365","DOI":"10.1039\/D3RA02969G","article-title":"Nanoparticle-based drug delivery systems targeting cancer cell surfaces","volume":"13","author":"Hong","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.mtbio.2026.103740_bib186","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.7150\/thno.18879","article-title":"PSMA-targeted theranostic nanocarrier for prostate cancer","volume":"7","author":"Flores","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2026.103740_bib187","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/nnm-2022-0198","article-title":"Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer","volume":"18","author":"Shahidi","year":"2023","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.mtbio.2026.103740_bib188","first-page":"433","article-title":"Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer","volume":"6","author":"Liang","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105231","article-title":"Molecular alterations of muc1 and their therapeutic exploitation: emerging opportunities in cancer therapy","volume":"221","author":"Khan","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mtbio.2026.103740_bib190","article-title":"Targeting antigen-presenting cells to enhance the tumor-spleen immunity cycle through liposome-neoantigen vaccine","volume":"12","author":"Xu","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.mtbio.2026.103740_bib191","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib192","article-title":"Immunotherapeutic agents for intratumoral immunotherapy","volume":"11","author":"Shyr","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.mtbio.2026.103740_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.mtbio.2026.103740_bib194","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103740_bib195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mtbio.2026.103740_bib196","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1038\/s41467-023-42155-z","article-title":"Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103740_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1739","article-title":"Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy","volume":"14","author":"Boone","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103740_bib198","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103740_bib199","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16060795","article-title":"Nano-delivery of immunogenic cell death inducers and immune checkpoint blockade agents: single-nanostructure strategies for enhancing immunotherapy","volume":"16","author":"Moon","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103740_bib200","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1578146","article-title":"Advancements in bladder cancer immunotherapy: a focus on intravesical approaches","volume":"16","author":"Tang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103740_bib201","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.urolonc.2024.01.201","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with BCG-unresponsive carcinoma in situ of the bladder: 36-MONTH follow-up from a phase 3 trial","volume":"42","author":"Boorjian","year":"2024","journal-title":"Urol. Oncol.: Seminars and Original Investigations"},{"key":"10.1016\/j.mtbio.2026.103740_bib202","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib203","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus calmette-gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib204","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.apsb.2026.01.019","article-title":"Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: advances and outlook","volume":"16","author":"Zhang","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2026.103740_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114587","article-title":"Nanomedicine-mediated modulation of tumor metabolism for enhanced immunotherapy","volume":"390","author":"Liu","year":"2026","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib207","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib208","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.mtbio.2026.103740_bib209","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103740_bib210","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd2290","article-title":"Molecular imaging in drug development","volume":"7","author":"Willmann","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103740_bib211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103740_bib212","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib213","first-page":"177","article-title":"A review of the current scientific and regulatory status of nanomedicines and the challenges ahead","volume":"65","author":"Hock","year":"2011","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.mtbio.2026.103740_bib214","first-page":"5144","article-title":"Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients","volume":"51","author":"Dalton","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103740_bib215","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1038\/s41467-022-34438-8","article-title":"Measurements of heterogeneity in proteomics analysis of the nanoparticle protein corona across core facilities","volume":"13","author":"Ashkarran","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103740_bib216","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnci\/84.12.951","article-title":"Metastatic model for human prostate cancer using orthotopic implantation in nude mice","volume":"84","author":"Stephenson","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mtbio.2026.103740_bib217","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700831","article-title":"Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications","volume":"7","author":"Croissant","year":"2018","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.103740_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112800","article-title":"Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: advancements and future perspectives","volume":"206","author":"Sameer Khan","year":"2024","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.mtbio.2026.103740_bib219","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/pros.23508","article-title":"A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases","volume":"78","author":"Linxweiler","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.mtbio.2026.103740_bib220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103740_bib221","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.2174\/092986712800784685","article-title":"Image-guided nanosystems for targeted delivery in cancer therapy","volume":"19","author":"Iyer","year":"2012","journal-title":"Curr. Med. Chem."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:48:45Z","timestamp":1793450925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426009853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":221,"alternative-id":["S2590006426009853"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103740","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103740"}}